Standout Papers
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial (2012)
- Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors (2004)
Immediate Impact
2 by Nobel laureates 18 from Science/Nature 70 standout
Citing Papers
Tumour vasculature at single-cell resolution
2024 StandoutNature
Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy
2022 Standout
Works of D. Voliotis being referenced
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
2006
Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors
2004 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| D. Voliotis | 1342 | 954 | 932 | 46 | 2.9k | |
| John Kauh | 862 | 1023 | 1334 | 105 | 3.0k | |
| Chetan Lathia | 1312 | 2014 | 1549 | 53 | 4.4k | |
| Gerold Meinhardt | 2706 | 1010 | 1277 | 57 | 4.7k | |
| Francesco Galimi | 737 | 1101 | 1148 | 35 | 2.4k | |
| Claus‐Henning Köhne | 1082 | 756 | 3069 | 73 | 4.2k | |
| Paolo Abada | 1143 | 586 | 625 | 62 | 2.2k | |
| Justin L. Ricker | 536 | 2446 | 1164 | 63 | 3.9k | |
| Robert Stagg | 700 | 807 | 1360 | 59 | 3.2k | |
| Frank Cihon | 900 | 1071 | 2468 | 32 | 3.7k | |
| Ian Walters | 742 | 604 | 531 | 56 | 2.5k |
All Works
Loading papers...